Patents by Inventor Shirong Zhu
Shirong Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11917911Abstract: Disclosed are a small-molecule electron donor material with an electron-deficient heterocyclic core, preparation and application thereof, belonging to technical field of solar cells. According to the present application, a brand-new electron-deficient heterocyclic unit which has never been applied to an organic solar cell is used as a core unit to prepare a small-molecule electron donor material with an A-D-A?-D-A skeleton structure, and the molecular structure of the small-molecule electron donor material is shown in formula (I).Type: GrantFiled: January 19, 2023Date of Patent: February 27, 2024Assignees: TAIZHOU UNIVERSITY, TAIZHOU HUIMO TECHNOLOGY CO., LTDInventors: Shirong Lu, Liu Zhu
-
Publication number: 20230165403Abstract: The present disclosure provides a silicon nitride ceramic heating and ignition device for a granular fuel barbecue oven, including a combustion chamber and a fixing pipe. An outer wall of the combustion chamber is welded to one end of the fixing pipe, the fixing pipe is communicated with an interior of the combustion chamber, and air inlet holes and air flow holes are defined in the two sides of the fixing pipe. One end of the fixing pipe is fixedly connected with a stainless steel sheet bending support, and the heat dissipation ceramic flange sleeve and one end flange port of the fixing pipe are connected with a boss positioning center. An inner cavity of the heat dissipation flange ceramic sleeve is bonded with the silicon nitride ignition rod.Type: ApplicationFiled: January 28, 2022Publication date: June 1, 2023Inventor: SHIRONG ZHU
-
Patent number: 9855230Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:Type: GrantFiled: September 3, 2015Date of Patent: January 2, 2018Assignee: ViiV HEALTHCARE UK (NO.5) LIMITEDInventors: Makonen Belema, John A. Bender, Brett Beno, Robert G. Gentles, Guo Li, Nicholas A. Meanwell, Annapurna Pendri, Zhong Yang, Shirong Zhu
-
Publication number: 20170304239Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:Type: ApplicationFiled: September 3, 2015Publication date: October 26, 2017Applicant: ViiV Healthcare UK (No.5) LimitedInventors: Makonen BELEMA, John A. BENDER, Brett BENO, Robert G. GENTLES, Guo LI, Nicholas A. MEANWELL, Annapurna PENDRI, Zhong YANG, Shirong ZHU
-
Publication number: 20140011700Abstract: The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer.Type: ApplicationFiled: March 23, 2012Publication date: January 9, 2014Inventors: Eric T. Baldwin, Patricia Ann McDonnell, Suzanne Edavettal, Hal Lewis, Bradley C. Pearce, David R. Langley, Christopher W. Cianci, Linda Discotto, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Patent number: 8362004Abstract: A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N, —O, or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH3, —CH2F, or —CH?CH2; W is —NO2, —Cl, —Br, —CHO, —CH?CH2, or —CN; X is —Cl, —CH3, or —CN; Y is —CH or —N; and Z is C1-C6 alkyl, C3-C6 cycloalkyl, substituted aryl, substituted heteroaryl, OR1, or NHR1, wherein R1 is selected from the group of H, aryl, heteroaryl, C1-C6 alkyl and C3-C6 cycloalkyl. This compound is useful in compositions for the prevention and treatment of influenza virus.Type: GrantFiled: September 6, 2011Date of Patent: January 29, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Christopher W. Cianci, Samuel Gerritz, Guo Li, Bradley C. Pearce, Annapurna Pendri, Shuhao Shi, Weixu Zhai, Shirong Zhu
-
Publication number: 20120245176Abstract: A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N, —O, or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH3, —CH2F, —CHF2 or —CH?CH2; V is —H, —CH3 or ?O; W is —NO2, —Cl, —Br, —CH2OH, or —CN; X is —Cl, —Br, —F, —CH3, —OCH3, or —CN; Y is —CH or —N; and Z is —CH or —N. This compound is useful in compositions for the prevention and treatment of influenza virus.Type: ApplicationFiled: September 23, 2011Publication date: September 27, 2012Inventors: Christopher W. Cianci, Samuel Gerritz, Sean Kim, David R. Langley, Guo Li, Bradley C. Pearce, Annapurna Pendri, Shuhao Shi, Weixu Zhai, Shirong Zhu
-
Publication number: 20120238539Abstract: A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N, —O, or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH3, —CH2F, or —CH?CH2; W is —NO2, —Cl, —Br, —CHO, —CH?CH2, or —CN; X is —Cl, —CH3, or —CN; Y is —CH or —N; and Z is C1-C6 alkyl, C3-C6 cycloalkyl, substituted aryl, substituted heteroaryl, OR1, or NHR1, wherein R1 is selected from the group of H, aryl, heteroaryl, C1-C6 alkyl and C3-C6 cycloalkyl. This compound is useful in compositions for the prevention and treatment of influenza virus.Type: ApplicationFiled: September 6, 2011Publication date: September 20, 2012Inventors: Christopher W. Cianci, Samuel Gerritz, Guo Li, Bradley C. Pearce, Annapurna Pendri, Shuhao Shi, Weixu Zhai, Shirong Zhu
-
Patent number: 7732434Abstract: There is provided a series of heterocyclic-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: April 8, 2008Date of Patent: June 8, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Shuhao Shi, Samuel Gerritz, Shirong Zhu
-
Patent number: 7678784Abstract: There is provided a series of oxime-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: November 15, 2007Date of Patent: March 16, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Yong-Jin Wu, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Patent number: 7612069Abstract: There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: June 20, 2006Date of Patent: November 3, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Samuel Gerritz, Weixu Zhai, Shuhao Shi, Shirong Zhu, Andrew C. Good, Lorin A. Thompson, III
-
Publication number: 20080262055Abstract: There is provided a series of heterocyclic-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: April 8, 2008Publication date: October 23, 2008Inventors: Shuhao Shi, Samuel Gerritz, Shirong Zhu
-
Patent number: 7408071Abstract: There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: March 29, 2007Date of Patent: August 5, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Kenneth M. Boy, Shirong Zhu, John E. Macor, Shuhao Shi, Samuel Gerritz
-
Patent number: 7390925Abstract: There is provided a series of substituted oxime-containing acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: March 29, 2007Date of Patent: June 24, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Yong-Jin Wu, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Publication number: 20080139523Abstract: There is provided a series of oxime-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: November 15, 2007Publication date: June 12, 2008Inventors: Yong-Jin Wu, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Publication number: 20070232679Abstract: There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: March 29, 2007Publication date: October 4, 2007Inventors: Kenneth M. Boy, Shirong Zhu, John E. Macor, Shuhao Shi, Samuel Gerritz
-
Publication number: 20070232581Abstract: There is provided a series of substituted oxime-containing acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: March 29, 2007Publication date: October 4, 2007Inventors: Yong-Jin Wu, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Patent number: 7273882Abstract: There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: June 20, 2006Date of Patent: September 25, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Publication number: 20070015754Abstract: There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: June 20, 2006Publication date: January 18, 2007Inventors: Samuel Gerritz, Andrew Good, Lorin Thompson, Weixu Zhai, Shuhao Shi, Shirong Zhu
-
Publication number: 20060287287Abstract: There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: ApplicationFiled: June 20, 2006Publication date: December 21, 2006Inventors: Samuel Gerritz, Shuhao Shi, Shirong Zhu